Overview: Herpes Simplex Virus 1 and 2 IgG TestIntroduction: The Herpes Simplex Virus 1 and 2 IgG Test detects IgG antibodies to HSV-1 and HSV-2 to confirm past infection, causing sores or genital issues. Aligned with 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, counseling, and improving outcomes in serology for patients with suspected herpes infections, aiding in partner management and recurrence prevention.
Other Names: HSV 1+2 IgG Assay, Herpes Simplex Immunity Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HSV antibody testing began in the 1980s with herpes research. Combined HSV-1/2 IgG immunoassays improved in the 1990s, enhancing past infection detection.
Purpose: Confirms past HSV-1 and HSV-2 infections, guides counseling, and monitors anti-HSV IgG in patients with sores or genital issues.
Test Parameters: 1. HSV 1+2 IgG
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like sores, genital issues, or neurological symptoms, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum or CSF within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document sores, genital issues, neurological symptoms, or history of HSV exposure. Include current medications, especially antivirals, and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for counseling or antiviral therapy.
Procedural Considerations: Uses an immunoassay to detect anti-HSV-1 and HSV-2 IgG antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for partner counseling.
Factors Affecting Result Accuracy: Improper sample handling or cross-reactivity between HSV-1 and HSV-2 can affect results. Early infection may yield false negatives.
Clinical Significance: Positive anti-HSV-1/2 IgG indicates past HSV infection, guiding counseling and antiviral therapy. Negative results suggest no prior exposure or early infection.
Specialist Consultation: Consult an infectious disease specialist or dermatologist for result interpretation and management planning.
Additional Supporting Tests: HSV-1/2 IgM, HSV PCR, or viral culture to confirm active or recent HSV infection.
Test Limitations: Cannot distinguish active from past infection. Cross-reactivity between HSV-1 and HSV-2 may occur. Clinical correlation is needed.
References: IDSA Herpes Guidelines, 2023; Clinical Infectious Diseases, Corey L, 2022.
